2022
Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry.
Alvi MA, Asher AL, Michalopoulos GD, Grills IS, Warnick RE, McInerney J, Chiang VL, Attia A, Timmerman R, Chang E, Kavanagh BD, Andrews DW, Walter K, Bydon M, Sheehan JP. Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry. Journal Of Neurosurgery 2022, 137: 985-998. PMID: 35171833, DOI: 10.3171/2021.10.jns211410.Peer-Reviewed Original ResearchMultivariable Cox proportional hazards analysisCox proportional hazards analysisAdministration of immunotherapyProportional hazards analysisStereotactic radiosurgeryIntracranial metastatic lesionsMetastatic lesionsOverall progressionLesion responseInitial stereotactic radiosurgeryMultifraction stereotactic radiosurgeryProgressive intracranial diseaseNeuro-Oncology criteriaOutcomes of patientsReal-world registryResponse Evaluation CriteriaGood local controlIntracranial metastatic diseaseKaplan-Meier analysisCommon primary tumorHazard of progressionLarger lesion sizeSingle-fraction treatmentLesion regressionMedian survival
2016
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery
Qian JM, Yu JB, Kluger HM, Chiang VL. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 2016, 122: 3051-3058. PMID: 27285122, PMCID: PMC5030143, DOI: 10.1002/cncr.30138.Peer-Reviewed Original ResearchConceptsMedian percent reductionImmune checkpoint therapyLesional responseStereotactic radiosurgeryCheckpoint therapyLesion volumeAnti-cytotoxic T-lymphocyte-associated protein 4Anti-programmed cell death protein 1T-lymphocyte-associated protein 4Anti-PD-1 therapyGreater median percent reductionsCell death protein 1Administration of immunotherapyWeeks of immunotherapyMelanoma brain metastasesDeath protein 1Type of immunotherapyWilcoxon rank sum testRank sum testNonconcurrent therapyBrain metastasesMelanoma patientsTreatment of cancerSingle institutionPercent reduction